Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
grip strength
hepatocellular carcinoma
lenvatinib
modified albumin-bilirubin grade
sarcopenia
skeletal muscle index
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Aug 2020
03 Aug 2020
Historique:
received:
26
06
2020
revised:
25
07
2020
accepted:
31
07
2020
entrez:
7
8
2020
pubmed:
7
8
2020
medline:
7
8
2020
Statut:
epublish
Résumé
Although sarcopenia is characterized by a loss of muscle strength and skeletal muscle mass, few studies have evaluated the effect of muscle strength on hepatocellular carcinoma (HCC) patients. We evaluated the impact of sarcopenia-related factors (grip strength (GS) and the skeletal muscle index (SMI)) on the survival among lenvatinib-treated unresectable HCC (u-HCC) patients. This single-center cohort study was conducted at a university hospital. The study population included 63 lenvatinib-treated u-HCC patients managed between April 2018 and April 2020. A decreased GS and decreased SMI were found in 21 (33.3%) and 22 (34.9%) patients, respectively. The overall survival (OS) of the normal GS group was significantly higher than that of the decreased GS group, while that of the normal and decreased SMI groups did not differ markedly. There were no significant differences in the progression-free survival between the normal GS and decreased GS groups or the normal SMI and decreased SMI groups. A multivariate Cox proportional hazards model showed that modified albumin-bilirubin-grade (mALBI) 2b (hazard ratio (HR) 4.39) and a decreased GS (HR 3.55) were independently associated with an increased risk of poor prognosis. In addition to the hepatic functional reserve, a decreased GS was a poor prognostic factor in lenvatinib-treated u-HCC patients.
Identifiants
pubmed: 32756366
pii: cancers12082146
doi: 10.3390/cancers12082146
pmc: PMC7465794
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Liver Cancer. 2020 Jan;9(1):73-83
pubmed: 32071911
J Hepatol. 2015 Jul;63(1):131-40
pubmed: 25724366
Oncologist. 2019 Dec;24(12):e1460-e1466
pubmed: 31227648
Sci Rep. 2016 Jan 20;6:19457
pubmed: 26785759
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
PLoS One. 2018 Jun 18;13(6):e0198812
pubmed: 29912922
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Cancers (Basel). 2020 Jul 04;12(7):
pubmed: 32635536
Cancers (Basel). 2019 Jul 07;11(7):
pubmed: 31284682
Hepatol Res. 2016 Sep;46(10):951-63
pubmed: 27481650
J Gastroenterol. 2006 Sep;41(9):884-92
pubmed: 17048053
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Cancers (Basel). 2019 Aug 19;11(8):
pubmed: 31430945
Clin Nutr. 2017 Feb;36(1):49-64
pubmed: 27642056
Front Physiol. 2012 Jul 11;3:260
pubmed: 22934016
Oncologist. 2018 May;23(5):580-585
pubmed: 29222198
Chron Respir Dis. 2017 Feb;14(1):85-99
pubmed: 27923981
Hepatol Res. 2019 Dec;49(12):1414-1426
pubmed: 31408558
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
Liver Cancer. 2020 Apr;9(2):193-206
pubmed: 32399433
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Aliment Pharmacol Ther. 2016 Apr;43(7):765-77
pubmed: 26847265
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
United European Gastroenterol J. 2018 Aug;6(7):1039-1048
pubmed: 30228892
J Gerontol A Biol Sci Med Sci. 2006 Jan;61(1):72-7
pubmed: 16456196
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Clin Gastroenterol Hepatol. 2012 Feb;10(2):166-73, 173.e1
pubmed: 21893129
Cancer Med. 2019 Jul;8(8):3719-3728
pubmed: 31127698
J Gastroenterol. 2010 Feb;45(2):218-24
pubmed: 19882375
Hepatol Res. 2017 May;47(6):558-565
pubmed: 27480045
Nutrients. 2019 Sep 01;11(9):
pubmed: 31480635
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Gastroenterol Hepatol. 2020 Jan 24;:
pubmed: 31975438
Diagnostics (Basel). 2020 Apr 20;10(4):
pubmed: 32325995